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ABSTRACT
A consecutive series of 63 untreated patients undergo-
ing surgical resection for stage I-IV gastric adenocarcino-
mas (GCs) has been prospectively studied. Our purpose was
to analyze the predictive relevance of DNA ploidy, S-phase
fraction (SPF), and tissue levels of lysosomal proteinases
cathepsin D (CD), cathepsin B (CB), cathepsin L (CL), and
urokinase-type plasminogen activator (uPA) and that of the
intracellular cysteine proteinase inhibitor stefin A on clinical
outcome. All of the patients taking part in this study were
followed up for a median of 73 months. DNA aneuploidy was
present in 71% of the cases (45/63), whereas 9% of these
(4/45) showed multiclonality. Both DNA ploidy and SPF
were associated with tumor-node-metastasis (TNM) stage
and node status, whereas only DNA ploidy was related to
depth of invasion. CB, CL, uPA, but not CD, levels were
significantly higher in GC as compared to paired normal
mucosa, whereas stefin A levels were lower in tumor tissues.
CB levels were significantly associated with TNM stage,
nodal status, histological grade, and DNA ploidy. At univa-
riate analysis, only node involvement, advanced TNM stage,
DNA aneuploidy, and high SPF proved to be significantly
related to quicker relapse and to shorter overall survival,
whereas depth of invasion was related only to survival. With
multivariate analysis, only high SPF (>15.2%) was related
to risk of relapse (RR 5 8.50), whereas high SPF and DNA
aneuploidy were independently related to risk of death
(RR 5 1.88 and 2.09, respectively). Our preliminary pro-
spective study has identified SPF and DNA ploidy as impor-
tant biological indicators for predicting the outcome of pa-
tients with GC.
INTRODUCTION
The traditional factors of GC3 are still inadequate for the
prognostic characterization because patients with identical clin-
ical or pathological stages may differ widely in the clinical
evolution (1). It is therefore extremely important to define the
prognostic factors that may help to recognize the more aggres-
sive types of such tumors. Reliable and reproducible prognostic
indicators are being investigated to help clinicians identify high-
risk groups and address more rational treatment decisions. Thus,
the identification of factors more strictly related to tumor biol-
ogy may be useful in characterizing patients with a different
prognosis. Recently, more and more attention has been focused
on the cell kinetics of many human tumors with possible prog-
nostic significance, including gastrointestinal neoplasias (2). At
the present time, one of the most widely used approaches is
cellular proliferation rate measured by flow cytometric analysis
(SPF), proposed as a rapid, simple, and particularly versatile
method applicable to fresh, frozen, and paraffin-embedded tis-
sues. In fact, some reports have observed that SPF was an
independent prognostic variable in GC (3–5). Previous studies
have also identified a DI and/or DNA ploidy as a useful bio-
logical factor, which may predict the clinical outcome of GC
(4–8). Furthermore, a consistent bulk of investigations has
shown that the expression levels of lysosomal aspartic and
cysteine proteinase CD, CB, and CL and serine protease uPA
may be significantly altered in tumor cells and tissues as com-
pared to their normal counterpart (9, 10). These alterations
appear to be associated with the malignant progression of sev-
eral human neoplastic diseases including GC (10–16). How-
ever, recent studies indicate that at least for CB and CL, this
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phenomenon may very likely be due to an altered regulation
and/or decreased affinity of specific intracellular inhibitors of
these proteases (17, 18) or also, as recently reported for CB, the
amplification of the gene encoding for these enzymes (19, 20),
rather than to an increased enzyme activity per se.
The aims of this paper were, firstly, to compare DNA
ploidy and SPF, their possible relations to the proteinases CD,
CB, CL, and uPA, and that of SA, a specific intracellular
inhibitor of cysteine proteinases and clinicopathological fea-
tures; and secondly, to evaluate the possible prognostic role of
either DNA ploidy and SPF or proteinases in GC.
MATERIALS AND METHODS
Patient Features. Paired tumor and normal tissue sam-
ples collected (January 1992 to June 1996) by the Laboratory of
Oncobiology of the University of Palermo from a consecutive
series of 63 patients undergoing resective surgery for primary
operable GC at a single institution (Department of Anatomy,
Surgery, and Oncology) were prospectively studied. Briefly,
exclusion criteria included: (a) history of previous neoplasias,
and (b) prior chemotherapy or radiation therapy. Resection of
the primary GC was performed in all cases. All patients under-
went potentially curative tumor resection, including radical
lymph node dissection. To avoid evaluator variability, all resec-
tion specimens and microscopic slides had been meticulously
examined by a single pathologist (R. M. T.). In addition, the
same pathologist assessed tumor size and site, depth of invasion,
TNM stage, tumor grade (histological differentiation), and
lymph node metastasis. The depth of tumor invasion was also
evaluated histologically as reported by Watanabe et al. (13).
Tumors were staged according to the latest TNM classification
(21). Finally, metastatic cases were identified by clinical and
histopathological analyses of neoplastic cells in organs such as
lymph nodes, liver, and so forth along with the primary tumor.
Clinicopathological data of all patients were available (Table 1).
Postoperatively, all patients were checked at 3-month intervals
for the first 2 years, at 6-month intervals for the next 2 years,
and annually thereafter. The follow-up program included a
clinical examination, routine check of circulating tumor markers
(CEA, TPA, CA19.9, and CA72.4 assay), annual chest radiog-
raphy, and endoscopy. Abdominopelvic computed tomography
scan was also performed every year for the first 2 years. Disease
relapse (local recurrence or distant metastasis) was confirmed
histologically where possible. All of the patients with relapse
disease after surgery received a standard chemotherapeutic reg-
imen for GC (5-fluorouracil, epirubicin, methotrexate, etopo-
side, doxorubicin, cisplatin).
Tissue Handling. Multiple samples of the primary tumor
tissue were taken from different representative areas and pro-
cessed within 30 min of surgical resection or biopsy. All tissues
were carefully trimmed to remove as much nonneoplastic tissue
as possible, avoiding the nonviable areas. Furthermore, from
each patient, multiple samples of normal mucosa (as confirmed
by histology) were taken in a corresponding nontumor area as
far as possible from the tumor site to be used as a control for
biochemical/cytochemical and flow cytometric analysis. The
tissues were bisected, one-half of each sample was processed for
pathological examination, and the remaining half of the sample
pool was immediately frozen and stored at 280°C until ana-
lyzed. The adequacy of the material was checked on frozen
tissue sections, and only tissue samples with .80% tumor
content were used in subsequent biochemical/cytochemical and
flow-cytometric analysis.
Cellular DNA Content and SPF Flow Cytometric Ex-
amination. DNA flow cytometry was performed on mechan-
ically disaggregated samples of frozen tumor tissue as in previ-
ously described protocols (22). DNA histogram analysis was
carried out by the Multicycle Software Program (Phoenix Flow
Systems, San Diego, CA), including systematic background
substraction (23, 24). DNA ploidy, DI, and SPF were deter-
mined as previously reported (22). Briefly, healthy gastric mu-
cosa was used as an internal DNA-diploid control for each
sample. Tumors with a DI 5 1 were defined as DNA-diploid,
and tumors with lower or higher DI values were considered
DNA-aneuploid if they contained .10% aneuploid cells.
Tissue Extraction and Determination of CB, CD, CL,
uPA, and SA Tissue Content. Paired sets of tumor and
normal tissue specimens (70–210 mg) were thawed, minced,
and suspended at 25 mg/ml in a tissue homogenization buffer
[50 mM Tris-HCl, 5 mM EDTA, 0.5 mM DTT, and 0.2% v/v
Triton X-100 (pH 6.9)]. Samples were homogenized at 2°C in
Table 1 Patient characteristics (n 5 63)
No. patients (%)
Sex
Males 43 (68)
Females 20 (32)
Age (yr): range (39–79)
,60 18 (29)
60–69 26 (41)
#70 19 (30)
Tumor location
Antrum 15 (24)
Corpus 26 (41)
Fundus or cardia 22 (35)
Tumor size (cm)
#5 28 (44)
.5 35 (56)
Depth of invasiona
PS (2) 44 (70)
PS (1) 19 (30)
TNM stageb
I 15 (24)
II 25 (40)
III 18 (28)
IV 5 (8)
Node status
Node negative 17 (27)
Node positive 46 (73)
Histological gradec
G1 3 (5)
G2 25 (40)
G3 35 (55)
a PS (2), invasion into the muscularis propria or into the subserosa
without infiltrative growth; PS (1), invasion into the subserosa with
infiltrative growth (13).
b Stage I: T1N0M0; T1N1M0; T2N0M0. Stage II: T1N2M0; T2N1M0;
T3N0M0. Stage III: T2N2M0; T3N1M0; T4N0M0; T3N2M0; T4N1M0.
Stage IV: T4N2M0; any T, any N, M1.
c G1, G2, and G3: well-, moderately-, and poorly-differentiated
tumors, respectively.
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an ice slurry in a Willelms Polytron PT-10 homogenizer (Kine-
matica, Luzern, Switzerland) set to rotate at 9, with two bursts
of 30 s and a 1-min intercooling period. The homogenate was
centrifuged at 500 g for 10 min. The supernatant was respun at
13,000 g for 15 min at 4°C in a preparative ultracentrifuge
(Beckman Model L80). The 13,000-g supernatant (i.e., cytosol)
was stored at 280°C until assays. Total CD content was deter-
mined, as previously reported (25), by an antibody-based im-
munoenzymatic assay kit (Triton, Ciba Corning, Diagnostics,
Alameda, CA) according to the manufacturer’s instructions. The
detection limit was 0.018 pmol/ml. Total CB, CL, and SA tissue
levels were determined by commercially available solid phase
ELISA kits (KRKA d.d., Novo mesto, Slovenia) in cytosol
diluted 1:2 or 1:5 (v/v) according to the manufacturer’s protocol.
Antibodies used for CB and CL assays recognized mature
forms, precursor molecules, and inhibitor-cathepsin complexes.
For the determination of SA, MoAbs used in sandwich ELISA
were obtained by hybridoma cell lines different from those used
to produce other cysteine protease inhibitor MoAbs (26). The
minimal detectable concentrations were 0.9 ng/ml for CB, 1.6
ng/ml for CL, and 1.04 ng/ml for SA. uPA levels were deter-
mined by a commercially available immunoluminometric assay
kit (Byk Sangtec, Cormano, Italy). The MoAbs used bind either
to the proenzyme or to the active form as well as to the enzyme
bound to its receptor (uPA-R) or to its endogenous inhibitor
(PAI-1). The detection limit was reported to be ,0.005 ng/ml.
The cytosol protein content was determined by a commercially
available colorimetric micromethod kit (Sigma, St. Louis, MO).
Statistical Analysis. Because of their asymmetric distri-
bution, the Mann-Whitney U test was used to evaluate differ-
ences in proteinases and SPF values between the two categories
of DNA ploidy. The nonparametric Spearman correlation
method was used to evaluate the correlation between the pro-
teinases variables examined. DFS was measured from the day of
primary surgery to the date of first relapse (locoregional or
metastatic), and OS was measured from the day of surgery to the
date of death specifically due to the tumor. Clinical and mor-
phobiological variables were examined univariately by means of
the Kaplan-Meier method (27), and significance of differences
for each prognostic factor was assessed by the log-rank test and
Wilcoxon test or test for trend when appropriate (28). Multiva-
riate analysis was carried out by means of the Cox’s logistic
regression model using a backward procedure (29). The null
hypothesis b 5 0 was tested by the Wald statistic. The relative
contribution of clinicopathological and biological variables was
assessed by means of the likelihood ratio test. For the prognostic
variables contributing significantly to the model, the effect was
calculated in terms of RR and the associated 95% confidence
limits. The 0.05 level of probability was taken as significant.
RESULTS
Cellular DNA Content and S-Phase Evaluation. Ade-
quate DNA histograms were obtained for all normal and
tumoral gastric tissues by means of flow-cytometry. The
coefficients of variation of the diploid G0/G1 peak ranged
from 2.6% to 4.8% (mean, 3.6%). DNA aneuploidy was
found in 71% of the cases (45/63), while 9% of these (4/45)
showed multiclonality. The SPF ranged from 3.5% to 37.2%
(median, 15.2% and interquartile range, 12.1–19.1%). By
using the SPF median value as the cutoff point, tumors were
accordingly divided into low (#15.2%) and high (.15.2%)
SPF tumors. Table 2 gives a summary of the significant
associations of DNA ploidy and SPF to the clinicopatholog-
ical variables for GC. Both DNA ploidy and SPF were
associated with TNM stage and node status, whereas only
DNA ploidy was related with depth of invasion. Furthermore,
a significant association was found between flow cytometric
variables (DNA ploidy and SPF). No association was found
between DNA ploidy and SPF and any of the following
factors: age, sex, histological grade, tumor size, and tumor
site.
CB, CD, CL, SA, and uPA Activity Levels in Gastric
Tumor and Normal Tissues. Table 3 reports the tissue levels
of CD, CB, CL, uPA, and SA determined in GC and in the
corresponding normal mucosa. Only CB, CL, and uPA levels
were significantly increased in tumor tissue as compared to the
paired normal counterpart (P , .05 for CL and P , .01 for CB
Table 2 Significative relationships of DNA ploidy and SPF to clinicopathological variables
DNA ploidy
P
SPF
PDa AMon AMu1 #15.2% .15.2%
Depth of invasion
PS (2)a 18 23 3
PS (1) 0 18 1 ,0.01
TNM stage
I 10 4 1 13 2
II 8 15 2 14 11
III–IV 0 22 1 ,0.01 4 19 ,0.01
Node status
Node negative 11 5 1 15 2
Node positive 7 36 3 ,0.01 16 30 ,0.01
SPF
#15.2% 16 15 0
.15.2% 2 26 4 ,0.01
a D, DNA-diploid; AMon, DNA-aneuploid monoclonal; AMul, DNA-aneuploid multiclonal; PS (2), invasion into the muscularis propria or into
the subserosa without infiltrative growth; PS (1), invasion into the subserosa with infiltrative growth.
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and uPA; Table 3). Moreover, the SA levels were lower in
tumor tissue as compared to normal tissue; however, this de-
crease was not statistically significant. CD tumor levels were
significantly correlated with CB, uPA, and SA (P , .05), whereas
CB levels were correlated with CD, uPA, and SA but not with CL
(Table 4). SA levels correlate with all of the enzymes considered,
but not with CL. Moreover, CB levels were significantly associated
with TNM stage [I (median) 5 93.3; II 5 142.0; III-IV 5 159.8;
P , .05], node status [node negative (median) 5 91.5; node
positive 5 159.7; P , .06], histological grade [G1 (median) 5
63.2; G2 5 121.7; G3 5 159.8; P , .01] and DNA ploidy [Diploid
(median) 5 92.4; Aneuploid monoclonal 5 156.3; Aneuploid
multiclonal 5 250.9; P , .01].
Impact on Relapse and Survival. The median fol-
low-up of patients was 73 months (range, 12–108 months). At
the time of analysis (April 1998), 31 patients had relapsed (2 had
local-regional recurrence and 29 had distant metastases) and 30
had died of a tumor-related cause. The overall 5-year survival
was 45.8% (SE, 6.9) for the whole series. At the univariate
analysis, high stage, lymph-node positivity, DNA aneuploidy,
and high SPF proved to be significantly related to quicker
relapse and to shorter OS (Table 5), whereas depth of invasion
was related only to survival. Univariate analysis failed to reveal
any significant association between age, sex, histological grade,
tumor location, tumor size, CB, CD, CL, uPA, or SA, and
relapse, or survival. Fig. 1 shows the probability of disease-free
interval in relation to SPF; Fig. 2 shows the probability of OS by
SPF and DNA ploidy. In Cox’s model for multivariate analysis,
only the significant variables at univariate analysis were con-
sidered. The estimated hazards ratio was higher for SPF
(.15.2%), which appeared to be the most relevant indicator of
relapse (RR 5 8.50), whereas multiple regression analysis car-
ried out for OS showed that SPF and DNA ploidy provided
independent information for predicting risk of death (Table 6).
DISCUSSION
Many attempts have been made to find new prognostic
indicators for patients with GC to identify the subgroup with
highly aggressive tumors and a high likelihood of disease re-
lapse or death. Aggressive surgical approaches, such as ex-
tended lymph node dissection or at least intensive postoperative
therapy, might be options for these poor prognosis patients.
There is still some controversy as to whether or not the DNA
content and SPF are significant prognostic factors in GC. Sev-
eral reports have shown that patients with DNA-aneuploid
and/or high SPF tumors had a worse prognosis than those with
DNA-diploid and/or low SPF tumors (3–7). Recently, in a study
performed on fresh tumor specimens taken from 76 patients
with GC, Abad et al. (6) found that DNA aneuploidy, histolog-
ical type, and the presence of extranodal metastases were inde-
pendent predictors of OS. By contrast, SPF did not predict
patient outcome. These results agree with those of Setala et al.
(7) and Victorzon et al. (8), whose respective analysis of 289
and 242 GC cases led to the observation that DNA ploidy and
TNM stage significantly predicted OS, whereas no significant
difference was found between SPF and prognosis. In contrast,
Lee et al. (3), in a 5-year prospective study of 217 patients with
GC, found that SPF was an independent prognostic variable,
whereas DNA ploidy was not associated with patient survival.
Finally, Yonemura et al. (4) and Ohyama et al. (5), in their
respective series of 493 and 117 patients with GC using multi-
variate analysis, found that DNA content and SPF (measured by
in vivo bromodeoxyuridine) were independent prognostic fac-
tors for OS. In our prospective study, which was based on
univariate and multivariate analyses with established prognostic
parameters (depth of invasion, TNM stage, node status, histo-
logical grade), we found that SPF was the only predictor of
disease relapse. Furthermore, the present study clearly shows
that both DNA ploidy and SPF are significant and independent
prognostic factors for OS in patients with GC who have under-
gone surgical resection. Our data also show that DNA multi-
ploidy represents the most powerful predictive indicator for
survival. These results suggest that studies of pathological prog-
nostic factors should include these biological variables. More-
over, because DNA analysis of endoscopic biopsy specimens
correlates well with surgical specimen DNA analysis (30), pre-
operative evaluation of flow cytometric variables may be useful
for predicting prognosis and choosing an adequate therapeutic
modality in patients with GC. The frequency of DNA aneu-
ploidy has been reported in a variable percentage of GC, from
36% to 71% (3–5, 6–8, 31, 32). In the present series, the
Table 3 CB, CD, CL, SA, and uPA levels in GC and paired normal gastric mucosa
CB
(ng/mg protein) P
CD
(pmol/mg protein) P
CL
(ng/mg protein) P
SA
(ng/mg protein) P
uPA
(ng/mg protein) P
Median
Mucosa 61.6 27.6 31.0 33.8 0.073
Tumor 142.0 ,0.01 22.5 NSa 33.3 ,0.05 1.7 NS 0.288 ,0.01
Range
Mucosa 0–408 0–77.4 0–68.6 0–643 0–1.12
Tumor 0–616 0–104 0–132.5 0–440 0–1.90
a NS, not significant.
Table 4 Correlation between CD, CB, CL, SA, and uPA in GC
CB CD CL SA uPA
CB ro 5 0.34 NSa ro 5 0.45 ro 5 0.28
P , 0.01 P , 0.01 P , 0.05
CD NS ro 5 0.25 ro 5 0.39
P 5 0.051 P , 0.01
CL NS NS
SA ro 5 0.36
P , 0.01
a NS, not significant.
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DNA-aneuploid rate (71%) was among the highest published
thus far. This is probably due to the use of multiple tissue
sampling of all cases studied, which greatly reduces the proba-
bility of missing DNA-aneuploid clones, and to the method
chosen to preserve the samples (freezing at 280°C), which
makes it possible to obtain a higher histogram resolution com-
pared with paraffin-embedded samples. The present study
shows that DNA ploidy and/or SPF are significantly associated
to depth of invasion, advanced clinical stage, and the presence
of lymph node metastases. Histopathological features are uni-
versally considered bad prognostic factors (14). Thus, the asso-
ciation with these variables suggests that flow cytometric indi-
cators are related to tumor aggressiveness. This is in accordance
with previous studies (6–8). Moreover, the perturbance of cell
cycle due to an increased proliferative activity of aneuploid
clones or to a prolongation of the S phase may enhance the risk
Fig. 1 Probability of DFS according to SPF (#15.2% versus .15.2%;
P , 0.01) in GC patients.
Fig. 2 Probabilty of OS according to (a) SPF (#15.2% versus
.15.2%; P , 0.01) and to (b) DNA ploidy status (DNA-diploid versus
DNA-aneuploid monoclonal versus DNA-aneuploid multiclonal; P ,
0.01) in GC patients.
Table 5 Univariate analysis of DFS and OS: distribution of patients for the significant variables according to Kaplan-Meier method
Variable
DFS (n 5 63)a OS (n 5 59)
DFS (%) 24 mo DFS (%) 60 mo O/Ea P OS (%) 36 mo OS (%) 60 mo O/E P
Depth of invasion
PS (2) 69 54 0.80
PS (1) 44 22 1.80 ,0.01
TNM stage
I 79 71 0.47 79 71 0.44
II 72 55 0.78 75 57 0.72
III–IV 40 18 1.94 ,0.01 34 11 2.29 ,0.01
Node status
Node negative 81 81 0.29 81 81 0.28
Node positive 55 34 1.36 ,0.01 56 31 1.41 ,0.01
DNA ploidy
Diploid 88 82 0.26 94 88 0.16
An. monoclonal 54 36 1.30 55 30 1.43
An. multiclonal 25 3.55 ,0.01 3.70 ,0.01
SPF
#15.2% 87 80 0.31 86 82 0.26
.15.2% 38 10 2.20 ,0.01 38 7 2.36 ,0.01
a O/E, observed/expected; PS (2), invasion into the muscularis propria or into the subserosa without infiltrative growth; PS (1), invasion into
the subserosa with infiltrative growth.
182 DNA ploidy, SPF, and Proteases in Gastric Cancer
Research. 
on May 28, 2013. © 2000 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
of genetic alterations. This phenomenon may result in the onset
of DNA-aneuploid cells, which would explain the significant
relationship between high SPF and aneuploidy observed in the
present study. Finally, unlike other investigators (7, 31), we did
not observe a significant association between DNA ploidy and
tumor site (fundus or cardia) as noted in three other series (3, 8,
33,). The present results confirm, in part, the data obtained from
other studies, which have reported elevated content or activity
levels of CB, CL, and uPA in GC tissues as compared to normal
gastric mucosa (11–13, 15, 16, 32).
However, only CB proved to be significantly associated
with most of the clinicobiological parameters of progression of
this tumor. Moreover, the intracellular cysteine proteinase in-
hibitor SA levels were lower in tumor tissue as compared to
those in its normal counterpart. These results indicate that the
alterated regulation of cysteine proteinases/SA ratio at the tumor
level may facilitate the progression of GC. In fact, this phenom-
enon has been observed “in vitro ” in human cancer cell lines,
and it has proved to be associated with a more malignant
phenotype (34, 35). Furthermore, decreased levels of SA have
also been seen “in vivo ” in different human tumors of epithelial
origin and have proved to be associated with the metastatic
potential and differentiation of these tumors (11, 18, 19). These
data suggest that the increased level of CB, together with other
proteolytic enzyme (metalloproteases), which appear to deter-
mine the malignant phenotype of GC, may play a major role in
the progression of this tumor (34, 36, 37). However, the recent
observations, which showed that proteinase inhibitors at subin-
hibitor concentrations may act as mitogens thus facilitating cell
proliferation (19, 35), indicate that SA may also directly share
the malignant progression of GC with a mechanism not related
to its proteinase-inhibiting activity. This may in part explain the
direct and not the inverse correlation, which might be expected,
observed between CB and SA at the tumor level. On the other
hand, conflicting results have been obtained regarding the dis-
tribution of CD. In fact, unlike the results reported in other
studies (14, 16), we did not observe any significant difference in
the levels of this protease between GC and normal mucosa or
the association with most of the clinicobiological parameters
considered, including disease relapse and death. These conflict-
ing results may be partly explained by the different methodolog-
ical approaches used to assess this parameter (i.e., immunohis-
tochemistry versus immunoenzyme assay). Our investigations
also showed significantly higher levels of uPA content in tumor
tissue as compared to those in normal tissue; no significant
association was found, however, between the uPA system and
the clinicobiological parameters of GC. These results are partly
in agreement with those from other studies (12, 16, 37) and
further indicate that the evaluation of the single components of
the uPA system, namely the uPA receptor or uPA inhibitors
PAI-1 and PAI-2, may be more appropriate for the assessment
of the prognostic significance of this serine protease in human
cancer (15, 16). However, it cannot be ruled out that the differ-
ent results we obtained on the prognostic significance of the
uPA complex may also be due to the different number of
patients evaluated in our study.
In conclusion, DNA ploidy and SPF may be reasonably
considered as indicators of biological and clinical aggressive-
ness. If our results are confirmed in larger prospective studies, it
might be possible to add such variables to other prognostic
factors for more aggressive strategies such as extended lymph
node dissection or intensive postoperative therapy in high risk
groups (patients with high SPF and/or DNA-aneuploid tumors)
to prevent disease relapse or death. In addition, the clinical
impact of the CB/SA system as biochemical prognostic param-
eters in this tumor has still to be sufficiently assessed.
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